MA38849A1 - Nouveaux composés d'indazole pour le traitement du diabete et leur procede de preparation - Google Patents

Nouveaux composés d'indazole pour le traitement du diabete et leur procede de preparation

Info

Publication number
MA38849A1
MA38849A1 MA38849A MA38849A MA38849A1 MA 38849 A1 MA38849 A1 MA 38849A1 MA 38849 A MA38849 A MA 38849A MA 38849 A MA38849 A MA 38849A MA 38849 A1 MA38849 A1 MA 38849A1
Authority
MA
Morocco
Prior art keywords
diabetes
preparation
treatment
indazole compounds
novel indazole
Prior art date
Application number
MA38849A
Other languages
English (en)
Other versions
MA38849B1 (fr
Inventor
Dumbala Srinivasa Reddy
Chaitanya Saxena
Kashinath Komirishetty
Original Assignee
Council Scient Ind Res
Shantani Proteome Analytics Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res, Shantani Proteome Analytics Pvt Ltd filed Critical Council Scient Ind Res
Publication of MA38849A1 publication Critical patent/MA38849A1/fr
Publication of MA38849B1 publication Critical patent/MA38849B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Le brevet divulgue de nouveaux composés d'indazole de formule générale 1 et des analogues de ceux-ci, leur utilisation pour le traitement du diabète, des complications diabétiques, du dysfonctionnement cardiovasculaire ou de maladies associées, des compositions pharmaceutiques les contenant et leurs procédés de préparation.
MA38849A 2013-07-31 2014-07-31 Nouveaux composés d'indazole pour le traitement du diabete et leur procede de preparation MA38849B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2296DE2013 2013-07-31
PCT/IN2014/000507 WO2015015519A1 (fr) 2013-07-31 2014-07-31 Nouveaux composés d'indazole et leur procede de preparation

Publications (2)

Publication Number Publication Date
MA38849A1 true MA38849A1 (fr) 2017-12-29
MA38849B1 MA38849B1 (fr) 2018-09-28

Family

ID=51795688

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38849A MA38849B1 (fr) 2013-07-31 2014-07-31 Nouveaux composés d'indazole pour le traitement du diabete et leur procede de preparation

Country Status (19)

Country Link
US (1) US9737510B2 (fr)
EP (1) EP3027605B1 (fr)
JP (1) JP6474808B2 (fr)
KR (1) KR20160053916A (fr)
CN (1) CN106103427B (fr)
AU (1) AU2014297912A1 (fr)
BR (1) BR112016002176A2 (fr)
CA (1) CA2919953A1 (fr)
DK (1) DK3027605T3 (fr)
EA (1) EA201690240A1 (fr)
ES (1) ES2656475T3 (fr)
GE (1) GEP20186812B (fr)
MA (1) MA38849B1 (fr)
MD (1) MD20160019A2 (fr)
MX (1) MX2016001331A (fr)
MY (1) MY176807A (fr)
SG (1) SG11201600744UA (fr)
WO (1) WO2015015519A1 (fr)
ZA (1) ZA201601177B (fr)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436913A (en) 1980-09-05 1984-03-13 Siegfried Aktiengesellschaft 1H- and 2H- indazole derivatives
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
WO1999009986A1 (fr) * 1997-08-22 1999-03-04 Kyowa Hakko Kogyo Co., Ltd. Derives de 4-aminoquinazoline
AU2201699A (en) * 1997-12-19 1999-07-12 Eli Lilly And Company Hypoglycemic imidazoline compounds
JP2000154139A (ja) * 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
WO2002083648A1 (fr) 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazole
JP2005507922A (ja) 2001-09-19 2005-03-24 ファルマシア・コーポレイション 炎症の治療のための置換されたインダゾール化合物
US20040009976A1 (en) 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
US6878735B2 (en) 2002-05-31 2005-04-12 Board Of Trustees Of Michigan State University Multi-substituted imidazolines and method of use thereof
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
EP1893569A4 (fr) * 2005-06-10 2009-08-05 Elixir Pharmaceuticals Inc Composes sulfonamide et leurs utilisations
EP2464231A4 (fr) 2009-08-10 2013-02-06 Samumed Llc Indazoles utiles comme inhibiteurs de la voie de signalisation de wnt/bêta-caténine et utilisations thérapeutiques de ceux-ci
US7947728B1 (en) 2009-11-11 2011-05-24 Hoffmann-La Roche Inc. Indole and indazole analogs as glycogen synthase activators

Also Published As

Publication number Publication date
ZA201601177B (en) 2017-11-29
MA38849B1 (fr) 2018-09-28
MX2016001331A (es) 2017-02-06
BR112016002176A2 (pt) 2017-08-01
MD20160019A2 (ro) 2016-06-30
WO2015015519A1 (fr) 2015-02-05
CN106103427B (zh) 2019-07-16
US9737510B2 (en) 2017-08-22
DK3027605T3 (en) 2018-01-22
CA2919953A1 (fr) 2015-02-05
JP2016525570A (ja) 2016-08-25
SG11201600744UA (en) 2016-02-26
EP3027605B1 (fr) 2017-11-08
ES2656475T3 (es) 2018-02-27
CN106103427A (zh) 2016-11-09
MY176807A (en) 2020-08-21
EP3027605A1 (fr) 2016-06-08
AU2014297912A1 (en) 2016-02-25
EA201690240A1 (ru) 2016-10-31
JP6474808B2 (ja) 2019-02-27
GEP20186812B (en) 2018-01-25
KR20160053916A (ko) 2016-05-13
US20160185759A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
CR20210045A (es) Inhibidores de inflamasoma nlrp3
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA50240B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
FR3037957B1 (fr) Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA42232A (fr) Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant
FR2986002A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
EP2666471A4 (fr) Composition pharmaceutique pour la traitement de la rate et de l'estomac, ainsi que procédé de préparation de cette composition
MA37213B1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
MA38803A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
TN2014000112A1 (en) Ep1 receptor ligands
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
MA38190A2 (fr) Inhibiteurs d'autotaxine
EA201891710A1 (ru) Терапевтические соединения
EP2878305A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par stat-3, contenant un extrait ou une fraction de salvia plebeia r. br. en tant que principe actif
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
FR2981936B1 (fr) Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
EP2910246A4 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer, contenant enoblock comme principe actif
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.